Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Azilsartan Medoxomil 40 mg QD	280
Overall Study	STARTED	Azilsartan Medoxomil 80 mg QD	285
Overall Study	STARTED	Valsartan 320 mg QD	282
Overall Study	STARTED	Olmesartan 40 mg QD	290
Overall Study	STARTED	Placebo QD	154
Overall Study	COMPLETED	Azilsartan Medoxomil 40 mg QD	257
Overall Study	COMPLETED	Azilsartan Medoxomil 80 mg QD	255
Overall Study	COMPLETED	Valsartan 320 mg QD	254
Overall Study	COMPLETED	Olmesartan 40 mg QD	268
Overall Study	COMPLETED	Placebo QD	141
Overall Study	NOT COMPLETED	Azilsartan Medoxomil 40 mg QD	23
Overall Study	NOT COMPLETED	Azilsartan Medoxomil 80 mg QD	30
Overall Study	NOT COMPLETED	Valsartan 320 mg QD	28
Overall Study	NOT COMPLETED	Olmesartan 40 mg QD	22
Overall Study	NOT COMPLETED	Placebo QD	13

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00696436/flow